미국의 세포치료용 원료 시장 : 시장 규모, 점유율 및 동향 분석(제품별, 최종 용도별, 지역별), 부문별 예측(2025-2033년)

Market Size & Trends:

The U.S. cell therapy raw materials market size was estimated at USD 2.06 billion in 2024 and is projected to reach USD 9.37 billion by 2033, growing at a CAGR of 18.42% from 2025 to 2033. Growth is driven by the rising number of cell therapy approvals, increasing demand for GMP-grade and high-quality inputs, and advancements in regenerative medicine. In addition, expanding biomanufacturing capabilities, increased funding, and the growing role of CDMOs in therapeutic development are further propelling the market forward, as the industry prioritizes reliable, scalable, and regulatory-compliant raw materials to support clinical and commercial cell therapy programs.

Expanding Therapy Pipelines Drive Demand for Components

The U.S. cell and gene therapy raw materials industry is experiencing strong growth, driven by the increasing number of personalized therapies and the complexity of their manufacturing processes. As cell therapies transition from research to commercialization, demand for high-grade raw materials-such as culture media, plasmid DNA, growth factors, and viral vectors-has surged. Developers seek products that offer consistency, scalability, and regulatory compliance to support both clinical and commercial-scale production. Moreover, rising investments, facility expansions, and technology upgrades by raw material suppliers have further accelerated market momentum, strengthening the infrastructure supporting advanced therapy development.

This demand is reflected in the expanding pipeline of cell and gene therapy candidates progressing through clinical trials. As seen in the accompanying table, therapies like Anito cel (Arcellx/Gilead) and OTL 203 (Orchard Therapeutics) are advancing through Phase II and III stages, targeting complex conditions such as multiple myeloma and Hurler syndrome. These trials, along with others in early and mid-development phases, illustrate the diversity of indications and technologies being pursued.

The development of such therapies relies heavily on specialized raw materials for reproducible and compliant manufacturing. As a result, strategic partnerships between therapy developers and raw material providers are becoming increasingly common, highlighting the foundational role of raw materials in supporting innovation and driving long-term growth across the U.S. cell therapy landscape.

U.S. Cell Therapy Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. cell therapy raw materials market report based on the product, and end use:

• Product Scope Outlook (Revenue, USD Million, 2021 - 2033)
• Media
• Sera
• Cell Culture Supplements
• Antibodies
• Reagents & Buffers
• Others
• End Use Scope Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. End Use Segment
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Market Model
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising demand for cell therapies
    • 3.2.1.2. Advancements in research and development for cell-based therapies
    • 3.2.1.3. Technological Innovation
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with the production and procurement of raw materials
    • 3.2.2.2. Stringent regulations associated with cell therapies
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Cell Therapy Raw Materials Market: Product Movement Analysis
• 4.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
• 4.4. Media
  • 4.4.1. Media Market, 2021 - 2033 (USD Million)
• 4.5. Sera
  • 4.5.1. Sera Market, 2021 - 2033 (USD Million)
• 4.6. Cell Culture Supplements
  • 4.6.1. Cell Culture Supplements Market, 2021 - 2033 (USD Million)
• 4.7. Antibodies
  • 4.7.1. Antibodies Market, 2021 - 2033 (USD Million)
• 4.8. Reagents & Buffers
  • 4.8.1. Reagents & Buffers Market, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. End-use Business Analysis

• 5.1. End Use Segment Dashboard
• 5.2. U.S. Cell Therapy Raw Materials Market: End Use Movement Analysis
• 5.3. U.S. Cell Therapy Raw Materials Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
• 5.4. Biopharmaceutical & Pharmaceutical Companies
  • 5.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
• 5.5. CROs & CMOs
  • 5.5.1. CROs & CMOs Market, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Strategy Mapping
• 6.3. Company Position Analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Thermo Fisher Scientific Inc.
    • 6.4.1.1. Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic Initiatives
  • 6.4.2. Merck KGaA
    • 6.4.2.1. Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic Initiatives
  • 6.4.3. Actylis.
    • 6.4.3.1. Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic Initiatives
  • 6.4.4. ACROBiosystems
    • 6.4.4.1. Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic Initiatives
  • 6.4.5. STEMCELL Technologies
    • 6.4.5.1. Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic Initiatives
  • 6.4.6. Grifols, S.A.
    • 6.4.6.1. Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic Initiatives
  • 6.4.7. Charles River Laboratories
    • 6.4.7.1. Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic Initiatives
  • 6.4.8. RoosterBio, Inc.
    • 6.4.8.1. Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic Initiatives
  • 6.4.9. PromoCell GmbH
    • 6.4.9.1. Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic Initiatives
  • 6.4.10. Danaher
    • 6.4.10.1. Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic Initiatives
  • 6.4.11. Sartorius Stedim Biotech
    • 6.4.11.1. Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic Initiatives